Biomarker-guided strategy has potential for liver cancer treatment

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

An MD Anderson Cancer Center study discovered a cellular pathway tied to cancer may be beneficial in reducing side effects and extending duration of immunotherapy in some patients with hepatocellular carcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Joni D. Nelson, assistant director for the Office of Workforce Development at the MUSC Hollings Cancer Center, remembers the exact day a switch went off in her head and her career took a turn towards finding ways to improve public health.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login